Germany's Merck sees long-term growth in cancer drug Erbitux

[riky]

Germany's Merck sees long-term growth in cancer drug Erbitux

DARMSTADT, Germany (Reuters) - German healthcare company Merck KGaA expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin. Erbitux, which accounted for roughly 8 percent of Merck's 10.7 billion euros ($14.6 billion) in sales last year, in June was shown to be more effective at prolonging the lives of colorectal cancer patients than Roche's Avastin. Only patients whose tumors contain the non-mutated version of a gene called KRAS took part in the trial. ...

Source: You are not allowed to view links. Register or Login